SEP 24, 2019 07:00 PM PDT

Promising Drug for Prostate Cancer

WRITTEN BY: Nouran Amin

Using high-throughput screening methods, cancer researchers from the UK have identified some promising drug candidates to test thousands of molecules. Specifically, they studied a protein called-methylacyl-CoA racemase (AMACR) as a potential target for therapeutics in prostate cancers. The experiments show that reducing the AMACR protein makes cancer cells less aggressive and allows their behavior to be like normal cells.

“The protein AMACR has been shown to be present in larger quantities in aggressive prostate cancer cells, and this research group have successfully developed a technique to find the protein and monitor its activity. Further to this, they have now found certain compounds that can target this protein's activity in the lab, and stop the cancer cells in their tracks,” says Simon Grieveson, Head of Research Funding at Prostate Cancer UK.

The study examined more than 20,000 drug-like molecules that inhibit the activity of AMACR using a method known as simple color-change technique. The technique allows for quick assessment of active compounds and identification of new types of drugs. Findings were published in the journal Bioorganic Chemistry.

Lead author Dr Matthew Lloyd said: "Although previously identified drugs are very effective in laboratory tests, in practice they are difficult to use in therapies because their properties do not allow easy distribution throughout the body. We started this study because we wanted to identify drugs which would be easier to use therapeutically. Although the particular compounds identified in this study did not kill prostate cancer cells very effectively, it is very promising that drug-like molecules were identified,” says lead author of the study, Dr. Matthew Lloyd rom the University of Bath.

Learn more about prostate cancer:

“The research is still in its infancy and is some way off from clinical investigation, however this is certainly promising and we look forward to seeing how this research progresses over the coming years,” says Grieveson.

Source: Science Daily

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 14, 2019
Genetics & Genomics
NOV 14, 2019
DNA Construction Kit Could Drive Down Costs of Immune Therapy
Researchers at KU Leuven in Belgium have created a DNA construction kit that, when injected into muscle cells, enables sheep to produce new antibodies to f...
NOV 14, 2019
Drug Discovery & Development
NOV 14, 2019
Does Adderall Really Work for People without ADHD?
Adderall is a popular stimulant. Known to treat Attention Deficit Disorder (ADHD), those without the condition also use it to increase attention, focus and...
NOV 14, 2019
Drug Discovery & Development
NOV 14, 2019
Peptide-Based Therapeutics Advances Alzheimer Disease Research
Affecting 44 million individuals globally, Alzheimer’s disease (AD) is a form of dementia characterized by loss of brain cells, inflammation and vasc...
NOV 14, 2019
Drug Discovery & Development
NOV 14, 2019
Triple Drug Combo Extends Fruit Fly Lifespan
A study published in the Proceedings of the National Academy of Sciences (PNAS) suggests that a triple drug combination can extend the lifespan of a fruit ...
NOV 14, 2019
Drug Discovery & Development
NOV 14, 2019
Evolutionary-Busting Cancer Drug
Researchers at the Institute of Cancer Research in London have discovered that a new type of drug that blocks treatment in cancers. The drug works by inhib...
NOV 14, 2019
Genetics & Genomics
NOV 14, 2019
Gene-Editing Breakthrough for Cervical Cancer
Researchers at the The Menzies Health Institute Queensland have found a way to use gene therapy CRISPR-Cas9 to treat cervical cancer. The first treatment o...
Loading Comments...